Valneva (SARS-CoV-2 疫苗): 一种SARS-CoV-2 S protein抑制剂药物,由Valneva SE (Valneva SE)公司最早进行研发,目前全球最高研发状态为批准上市,作用机制: SARS-CoV-2 S protein抑制剂(冠状病毒刺突糖蛋白抑制剂),治疗领域: 感染,呼吸系统疾病,在研适应症: 新型冠状
We identified individuals who had a reimbursement code (D6584) for the RT-PCR test for the detection of SARS-CoV-2. The date of the first test for SARS-CoV-2 was designated as the index date. Recent use of HCQ was determined when the reimbursement records for drugs confirmed that HCQ ...
Due to the lack of data on asymptomatic SARS-CoV-2-positive persons in healthcare institutions, they represent an inestimable risk. Therefore, the aim of the current study was to evaluate the first 1,000,000 reported screening tests of asymptomatic staff